Literature DB >> 15318676

Treating bipolar disorder. Evidence-based guidelines for family medicine.

Roger S McIntyre1, Deborah A Mancini, Peter Lin, John Jordan.   

Abstract

OBJECTIVE: To provide an evidence-based summary of medications commonly used for bipolar disorders and a practical approach to managing bipolar disorders in the office. QUALITY OF EVIDENCE: Articles from 1990 to 2003 were selected from MEDLINE using the key words "bipolar disorder," "antiepileptics," "antipsychotics," "antidepressants," and "mood stabilizers." Good-quality evidence for many of these treatments comes from randomized trials. Lithium, divalproex, carbamazepine, lamotrigine, oxcarbazepine, and some novel antipsychotics all have level I evidence for treating various aspects of the disorder. MAIN MESSAGE: Treatment of bipolar disorder involves three therapeutic domains: acute mania, acute depression, and maintenance. Lithium has been a mainstay of treatment for some time, but antiepileptic drugs like divalproex, carbamazepine, and lamotrigine, along with novel antipsychotic drugs like olanzapine, risperidone, and quetiapine, alone or in combination, are increasingly being used successfully to treat acute mania and to maintain mood stability.
CONCLUSION: Bipolar disorder is more common in family practice than previously believed. Drug treatments for this complex disorder have evolved rapidly over the past decade, radically changing its management. Treatment now tends to be very successful.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15318676      PMCID: PMC2214573     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  40 in total

1.  A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.

Authors:  R R Conley; R Mahmoud
Journal:  Am J Psychiatry       Date:  2001-05       Impact factor: 18.112

Review 2.  Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents.

Authors:  S G Siris
Journal:  Am J Psychiatry       Date:  2000-09       Impact factor: 18.112

Review 3.  Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.

Authors:  R S McIntyre; S M McCann; S H Kennedy
Journal:  Can J Psychiatry       Date:  2001-04       Impact factor: 4.356

Review 4.  Reduced suicide risk during lithium maintenance treatment.

Authors:  L Tondo; R J Baldessarini
Journal:  J Clin Psychiatry       Date:  2000       Impact factor: 4.384

Review 5.  Onset of action of antipsychotics in the treatment of mania.

Authors:  M Tohen; T G Jacobs; P D Feldman
Journal:  Bipolar Disord       Date:  2000-09       Impact factor: 6.744

6.  Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire.

Authors:  R M Hirschfeld; J B Williams; R L Spitzer; J R Calabrese; L Flynn; P E Keck; L Lewis; S L McElroy; R M Post; D J Rapport; J M Russell; G S Sachs; J Zajecka
Journal:  Am J Psychiatry       Date:  2000-11       Impact factor: 18.112

7.  Does olanzapine have antidepressant properties? A retrospective preliminary study.

Authors:  S N Ghaemi; E L Cherry; J A Katzow; F K Goodwin
Journal:  Bipolar Disord       Date:  2000-09       Impact factor: 6.744

8.  A novel augmentation strategy for treating resistant major depression.

Authors:  R C Shelton; G D Tollefson; M Tohen; S Stahl; K S Gannon; T G Jacobs; W R Buras; F P Bymaster; W Zhang; K A Spencer; P D Feldman; H Y Meltzer
Journal:  Am J Psychiatry       Date:  2001-01       Impact factor: 18.112

Review 9.  Lamotrigine: a review of clinical studies in bipolar disorders.

Authors:  S Zerjav-Lacombe; E Tabarsi
Journal:  Can J Psychiatry       Date:  2001-05       Impact factor: 4.356

Review 10.  Novel treatments for bipolar disorder.

Authors:  C L Bowden
Journal:  Expert Opin Investig Drugs       Date:  2001-04       Impact factor: 6.206

View more
  2 in total

1.  Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy.

Authors:  William A Wolf; Gerald J Bieganski; Veronica Guillen; Laurence Mignon
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 2.  Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.